China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SZSE:000999
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
36.1253
51.82
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
Cash from Operating Activities
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SZSE:000999
|
Cash from Operating Activities
¥4.3B
|
CAGR 3-Years
27%
|
CAGR 5-Years
18%
|
CAGR 10-Years
15%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Cash from Operating Activities
¥3.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Cash from Operating Activities
¥1.2B
|
CAGR 3-Years
25%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
18%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Cash from Operating Activities
¥7.9B
|
CAGR 3-Years
39%
|
CAGR 5-Years
19%
|
CAGR 10-Years
18%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Cash from Operating Activities
¥5B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
65%
|
CAGR 10-Years
15%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Cash from Operating Activities
-¥615.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
Glance View
In the intricate landscape of China's healthcare sector, China Resources Sanjiu Medical & Pharmaceutical Co Ltd stands as a significant player, weaving its extensive roots in both traditional and modern medicine. Emerging from the fusion of innovation and heritage, the company operates under the wing of China Resources, a state-owned conglomerate. This affiliation affords it a robust platform to traverse the dual path of pharmaceutical manufacturing and healthcare services. The company primarily engages in the development, production, and sale of a diverse range of pharmaceutical products, from essential medicines to over-the-counter dietary supplements. These offerings include both Western-style pharmaceuticals and traditional Chinese medicines, such as its widely recognized "999" branded cold medicines, allowing the company to leverage its expertise in a market with growing demand for holistic health solutions. China Resources Sanjiu generates its revenue through multiple channels, capitalizing on both domestic and international market opportunities. By integrating research and development with an efficient distribution network, the company ensures that its products reach a broad consumer base. In recent years, the company has focused on enhancing its research capabilities, investing heavily in developing innovative drugs that address prevalent health challenges. Sales of their proprietary and branded products are supported by strategic marketing initiatives, which highlight Sanjiu's commitment to quality and efficacy. Furthermore, the company's synergy with its parent organization facilitates expansions and strategic partnerships, reinforcing its competitive advantage in an industry marked by rapid evolution and stringent regulatory landscapes. With a foothold in both retail and institutional markets, China Resources Sanjiu Medical & Pharmaceutical Co Ltd continues to play a pivotal role in enhancing access to healthcare across China and beyond.
See Also
What is China Resources Sanjiu Medical & Pharmaceutical Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
4.3B
CNY
Based on the financial report for Sep 30, 2024, China Resources Sanjiu Medical & Pharmaceutical Co Ltd's Cash from Operating Activities amounts to 4.3B CNY.
What is China Resources Sanjiu Medical & Pharmaceutical Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
15%
Over the last year, the Cash from Operating Activities growth was 8%. The average annual Cash from Operating Activities growth rates for China Resources Sanjiu Medical & Pharmaceutical Co Ltd have been 27% over the past three years , 18% over the past five years , and 15% over the past ten years .
You don't have any saved screeners yet
